Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Primary Sclerosing Cholangitis in Children: A Long–Term Follow–Up Study

Feldstein, Ariel E., Perrault, Jean, El-Youssif, Mounif, Lindor, Keith D., Freese, Deborah K., Angulo, Paul·2003·Hepatology

Abstract

Primary sclerosing cholangitis (PSC) is increasingly diagnosed in children and adolescents, but its long–term prognosis remains uncertain. The aim of this longitudinal, cohort study was to determine the long–term outcome of children with PSC. Fifty–two children with cholangiography–proven PSC (34 boys and 18 girls; mean age 13.8 ± 4.2 years; range, 1.5–19.6 years) who were seen at our institution over a 20–year period were followed–up for up to 16.7 years. Two thirds presented with symptoms and/or signs of PSC and 81% had concomitant inflammatory bowel disease (IBD). Twenty–five percent had total alkaline phosphatase activity within the normal range for the age group, but all of them had elevated γ–glutamyl transpeptidase levels. Autoimmune hepatitis overlapping with PSC was present in 35% of children. A positive but transient clinical and/or biochemical response occurred under therapy with ursodeoxycholic acid, alone or in combination with immunosuppressive medications. During follow–up, 11 children underwent liver transplantation for end–stage PSC and 1 child died. The median (50%) survival free of liver transplantation was 12.7 years. Compared with an age– and gender–matched U.S. population, survival was significantly shorter in children with PSC (P < .001). In a Cox regression model, lower platelet count, splenomegaly, and older age were associated with shorter survival. Presence of autoimmune hepatitis overlapping with PSC (P = .2) or medical therapy (P = .2) did not affect survival. In conclusion, PSC significantly decreases survival in this child population. Although pharmacologic therapy may improve symptoms and liver test results initially, it does not seem to impact the long–term outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2003.50289

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 256

Metadata

Authors
Feldstein, A. E., Perrault, J., El-Youssif, M., Lindor, K. D., Freese, D. K., & Angulo, P.
Venue
Hepatology
Published
2003-07
Volume
38
Issue
1
Pages
210-217
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2048437293
Cited by
256
References
28
FWCI
4.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary Sclerosing Cholangitis in Children: A Long–Term Follow–Up Study. https://app.cochat.ai/papers/10.1053/jhep.2003.50289
The paper
Feldstein, A. E., Perrault, J., El-Youssif, M., Lindor, K. D., Freese, D. K., & Angulo, P. (2003). Primary Sclerosing Cholangitis in Children: A Long–Term Follow–Up Study. Hepatology. https://doi.org/10.1053/jhep.2003.50289

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.